Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ViroStatics, an Italian-US biopharmaceutical company, has enered into a strategic partnership with Vichem Chemie, to identify, synthesize, screen and develop the next generation of AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) for the treatment of HIV/AIDS and other chronic diseases.
Subscribe to our email newsletter
ViroStatics claimed that AV-HALTS are a new class of drugs that combine direct anti-viral activity with a reduction in the chronically elevated immune system activation that is now known to play a major role in the progression of HIV disease, ultimately leading to AIDS. ViroStatics has brought AV-HALT, VS411, into Phase II development.
Franco Lori, president and CEO of ViroStatics, said: “Our new partnership brings together both companies’ substantial intellectual properties and significant libraries of Kinase Inhibitors.”
Gyorgy Keri, CEO of Vichem Chemie, said: “The expertise of ViroStatics in translating basic discoveries into clinical applications -from the bench to the bed side – is well appreciated. The Companies’ strengths are both complimentary and synergistic.
“We look forward to a successful partnership to identify new and exciting compounds that ViroStatics will develop into important new therapies against HIV/AIDS and other chronic diseases.”